INT80862

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1999
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 1.66
Pain Relevance 2.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A5) oxidoreductase activity (CYP3A5) endoplasmic reticulum (CYP3A5)
Anatomy Link Frequency
liver 1
CYP3A5 (Homo sapiens)
Pain Link Frequency Relevance Heat
vincristine 12 99.38 Very High Very High Very High
fluoxetine 8 97.96 Very High Very High Very High
antidepressant 6 96.40 Very High Very High Very High
sSRI 2 94.68 High High
Dopamine 6 92.68 High High
imagery 2 86.28 High High
Nucleus accumbens 3 83.52 Quite High
abdominal pain 2 83.20 Quite High
methotrexate 2 80.00 Quite High
Eae 3 79.08 Quite High
Disease Link Frequency Relevance Heat
Toxicity 2 98.24 Very High Very High Very High
Ileus 2 86.56 High High
Intestinal Pseudo-obstruction 4 85.04 High High
Constipation 3 84.36 Quite High
Pressure Volume 2 Under Development 12 83.80 Quite High
Abdominal Pain 2 83.20 Quite High
Epstein-barr Virus 2 76.36 Quite High
Attention Deficit Hyperactivity Disorder 1 75.00 Quite High
Infection 2 70.48 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 2 70.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Further, the results indicate that fluoxetine potentiates the effects of amphetamine by decreasing the metabolism of amphetamine, probably through inhibition of cytochrome P450 isozymes.
Negative_regulation (inhibition) of cytochrome P450 associated with fluoxetine
1) Confidence 0.57 Published 1999 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 10090650 Disease Relevance 0.07 Pain Relevance 1.06
HPP(+) formation followed Michaelis-Menten kinetics in microsomes, recombinant CYP3A4, and CYP3A5 with K(m) values of 24.4 +/- 8.9 microM, 18.3 +/- 4.9 microM, and 200.2 +/- 47.6 microM, respectively, and V(max) values of 157.6 +/- 13.2 pmol/min/mg of protein, 10.4 +/- 0.6 pmol/min/pmol P450, and 5.16 +/- 0.6 pmol/min/pmol P450, respectively.
Negative_regulation (followed) of CYP3A5
2) Confidence 0.43 Published 2003 Journal Drug Metab. Dispos. Section Abstract Doc Link 12584149 Disease Relevance 0 Pain Relevance 0.18
It is both a substrate and potent inhibitor of the liver cytochrome P450 isozyme CYP3A4.
Negative_regulation (inhibitor) of cytochrome P450 in liver
3) Confidence 0.42 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 0.14 Pain Relevance 0.03
Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor.
Negative_regulation (inhibitor) of CYP3A5
4) Confidence 0.40 Published 2009 Journal Pharm World Sci Section Abstract Doc Link 19757141 Disease Relevance 0.71 Pain Relevance 0.43
Vincristine is transported by P-gp and is metabolized via CYP3A5.
Negative_regulation (metabolized) of CYP3A5 associated with vincristine
5) Confidence 0.40 Published 2009 Journal Pharm World Sci Section Abstract Doc Link 19757141 Disease Relevance 0.73 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox